Loading articles...
Systemic therapies for atopic dermatitis require careful patient selection and monitoring to maximize benefit and minimize risk. This case highlights the importance of considering disease severity, patient comorbidities, and prior treatment responses when c...
Atopic dermatitis patients may benefit from novel therapies targeting GSDMD, a protein that appears to suppress keratinocyte differentiation. Inhibiting GSDMD could offer an alternative or adjunct to existing treatments like JAK inhibitors.
Gasdermin D (GSDMD), beyond its well-established role in pyroptosis, appears to directly influence keratinocyte differentiation in atopic dermatitis. Understanding this mechanism could lead to novel therapeutic strategies targeting skin barrier dysfunction.
Predicting acne recurrence remains challenging, impacting long-term management. A recent study proposes a nomogram for predicting recurrence, but its generalizability is questionable.
Atopic dermatitis management is evolving rapidly with new systemic therapies. This practical guide helps clinicians navigate the choice between biologics and JAK inhibitors, considering patient profiles and potential adverse effects.
Patients with chronic dermatologic conditions face a delicate balance between disease control and infection risk when using JAK inhibitors and biologics. This meta-analysis prompts clinicians to carefully evaluate individual patient risk profiles before ini...
Acne recurrence remains a frustrating challenge for both patients and dermatologists, impacting quality of life. This study attempts to identify key risk factors and develop a predictive model to mitigate this issue.
Dermatology patients on advanced immunomodulatory therapies face an elevated risk of infection, demanding vigilant monitoring. This meta-analysis prompts a crucial reevaluation of comparative safety profiles between JAK inhibitors and biologics in managing ...
Patients with atopic dermatitis (AD) are benefiting from the shift toward targeted systemic therapies that avoid broad immunosuppression. The evolution towards biologics and JAK inhibitors promises more precise management and fewer off-target effects, thoug...
The discovery of two new Mycobacterium species, *Mycobacterium camsae* and *Mycobacterium pumcae*, isolated from human skin infections, highlights the ongoing evolution of our understanding of microbial diversity. Clinicians should consider that conventiona...